Bronchiectasis Insanity: Doing the Same Thing over and over Again and Expecting Different Results?

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2019 Mar 26

PMID 30906533

Citations 7

Authors

Mark Metersky

James Chalmers

Affiliations

Soon will be listed here.

Abstract

Bronchiectasis is an increasingly common disease with a significant impact on quality of life and morbidity of affected patients. It is also a very heterogeneous disease with numerous different underlying etiologies and presentations. Most treatments for bronchiectasis are based on low-quality evidence; consequently, no treatments have been approved by the US Food and Drug Administration or the European Medicines Agency for the treatment of bronchiectasis. The last several years have seen numerous clinical trials in which the investigational agent, thought to hold great promise, did not demonstrate a clinically or statistically significant benefit. This commentary will review the likely reasons for these disappointing results and a potential approach that may have a greater likelihood of defining evidence-based treatment for bronchiectasis.

Citing Articles

National survey on pediatric respiratory physiotherapy U nits: primary ciliary dyskinesia and non-CF bronchiectasis.

Tani B, Ullmann N, Leone P, Boni A, Barbieri E, DAngelo M Ital J Pediatr. 2025; 51(1):67.

PMID: 40050996 PMC: 11887135. DOI: 10.1186/s13052-025-01904-0.

The Chronic Obstructive Pulmonary Disease (COPD)-Bronchiectasis Overlap Syndrome: Does My COPD Patient Have Bronchiectasis on Computed Tomography? "Frankly, My Dear, I Don't Give a Damn!".

Metersky M, Dransfield M Am J Respir Crit Care Med. 2023; 208(12):1265-1267.

PMID: 37796579 PMC: 10765396. DOI: 10.1164/rccm.202308-1468VP.

Evaluation of outcome reporting in clinical trials of physiotherapy in bronchiectasis: The first stage of core outcome set development.

Hamzeh H, Spencer S, Kelly C, Pilsworth S PLoS One. 2023; 18(3):e0282393.

PMID: 36928192 PMC: 10019700. DOI: 10.1371/journal.pone.0282393.

Bronchial gene expression alterations associated with radiological bronchiectasis.

Xu K, Diaz A, Duan F, Lee M, Xiao X, Liu H Eur Respir J. 2022; 61(1).

PMID: 36229050 PMC: 9881226. DOI: 10.1183/13993003.00120-2022.

Precision medicine in bronchiectasis.

Pembridge T, Chalmers J Breathe (Sheff). 2022; 17(4):210119.

PMID: 35035573 PMC: 8753699. DOI: 10.1183/20734735.0119-2021.

References

Daviskas E, Anderson S, Eberl S, Chan H, BAUTOVICH G . Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999; 159(6):1843-8. DOI: 10.1164/ajrccm.159.6.9809074. View

Papayannopoulos V, Staab D, Zychlinsky A . Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One. 2011; 6(12):e28526. PMC: 3235130. DOI: 10.1371/journal.pone.0028526. View

Seitz A, Olivier K, Adjemian J, Holland S, Prevots D . Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012; 142(2):432-439. PMC: 3425339. DOI: 10.1378/chest.11-2209. View

Nicolson C, Stirling R, Borg B, Button B, Wilson J, Holland A . The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012; 106(5):661-7. DOI: 10.1016/j.rmed.2011.12.021. View

Chalmers J, Smith M, McHugh B, Doherty C, Govan J, Hill A . Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012; 186(7):657-65. DOI: 10.1164/rccm.201203-0487OC. View

Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H . Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):660-7. DOI: 10.1016/S0140-6736(12)60953-2. View

Ryan N, Birring S, Gibson P . Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380(9853):1583-9. DOI: 10.1016/S0140-6736(12)60776-4. View

Stockley R, Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N . Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013; 107(4):524-33. DOI: 10.1016/j.rmed.2012.12.009. View

Altenburg J, de Graaff C, Stienstra Y, Sloos J, van Haren E, Koppers R . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013; 309(12):1251-9. DOI: 10.1001/jama.2013.1937. View

10.

Serisier D, Martin M, McGuckin M, Lourie R, Chen A, Brain B . Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013; 309(12):1260-7. DOI: 10.1001/jama.2013.2290. View

11.

Chalmers J, Goeminne P, Aliberti S, McDonnell M, Lonni S, Davidson J . The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2013; 189(5):576-85. PMC: 3977711. DOI: 10.1164/rccm.201309-1575OC. View

12.

Haworth C, Foweraker J, Wilkinson P, Kenyon R, Bilton D . Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014; 189(8):975-82. PMC: 4098097. DOI: 10.1164/rccm.201312-2208OC. View

13.

Barker A, ODonnell A, Flume P, Thompson P, Ruzi J, De Gracia J . Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014; 2(9):738-49. DOI: 10.1016/S2213-2600(14)70165-1. View

14.

Bilton D, Tino G, Barker A, Chambers D, Soyza A, Dupont L . Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014; 69(12):1073-9. DOI: 10.1136/thoraxjnl-2014-205587. View

15.

Quint J, Millett E, Joshi M, Navaratnam V, Thomas S, Hurst J . Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2015; 47(1):186-93. PMC: 4982534. DOI: 10.1183/13993003.01033-2015. View

16.

Goeminne P, Soyza A . Bronchiectasis: how to be an orphan with many parents?. Eur Respir J. 2016; 47(1):10-3. DOI: 10.1183/13993003.01567-2015. View

17.

Chalmers J, McDonnell M, Rutherford R, Davidson J, Finch S, Crichton M . The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. Respir Med. 2016; 112:51-8. DOI: 10.1016/j.rmed.2016.01.016. View

18.

Flume P, Clancy J, Retsch-Bogart G, Tullis D, Bresnik M, Derchak P . Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016; 15(6):809-815. DOI: 10.1016/j.jcf.2016.05.001. View

19.

Aliberti S, Masefield S, Polverino E, Soyza A, Loebinger M, Menendez R . Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J. 2016; 48(3):632-47. DOI: 10.1183/13993003.01888-2015. View

20.

McDonnell M, Aliberti S, Goeminne P, Dimakou K, Zucchetti S, Davidson J . Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016; 71(12):1110-1118. PMC: 5136700. DOI: 10.1136/thoraxjnl-2016-208481. View